I emailed IR and Dr. NP this morning after the PR.

I emailed IR and Dr. NP this morning after the PR. Below is the email I sent and the response I got from Dr. NP. I CCed Dr. NP on the email but did not expect an email from him. Given his response, we may not hear why Dr. RP was terminated, although I highly doubt this topic won’t come up at the dinner and/or CC next week. Lets hope this doesn’t effect the cancer trials.

My email:
CYDY IR,
My name is ——— ———- and I’m a shareholder of Cytodyn and have been since 2015.

Today’s press release informed shareholders that Dr. Pestell was terminated from his position as Chief Medical Officer, “for cause pursuant to the terms of his employment agreement with the Company and pursuant to the terms of his employment agreement.”

Will Dr. Pourhassan be discussing the reason for Dr. Pestell’s termination with shareholders during the the upcoming dinner or conference call? Many of us long term shareholders, and even new shareholders in the past year, increased our holding because Dr. Pestell came on board and brought Prostagene with him. We are disappointed to see him him leave the company and are interested if this is related to the delays in the mTNBC trial and if this will further delay cancer trials. Obviously CYDY retains the rights to Prostagene’s intellectual property, which is most important, but also loses Dr. Pestell’s expertise in CCR5 and cancer.

If any explanation can be given, even a simple one, it may put investors at ease. His termination may cause short term concern for the cancer pipeline and for CYDY overall but we hope that with upcoming milestones the news of Dr. Pestell’s termination, although unfortunate, will only be a small blip on this years radar.

Thanks,

———— ————

Dr. NP’s response:

Thank you for your support.

Dr. Massimo Cristofanilli is world expert, physician, in TNBC and CytoDyn’s Principle investigator in our current TNBC trial.

A given clinical trial requires CytoDyn to sign an agreement with Hospitals and physicians to enroll qualified patients and does not necessarily require a top scientist but top physician. We prove we can do this and can bring in top expert to get this done in the world of HIV as we are about to submit BLA for final approval for a product that was shelved by many top scientists of the world.

We will speak about the first patient injection for TNBC and look forward to our upcoming call with investors.

With best regards,
Nader